Revelation Biosciences Stock Analysis
| REVB Stock | USD 2.88 0.10 3.36% |
Revelation Biosciences is undervalued with Real Value of 5.32 and Target Price of 12.75. The main objective of Revelation Biosciences stock analysis is to determine its intrinsic value, which is an estimate of what Revelation Biosciences is worth, separate from its market price. There are two main types of Revelation Biosciences' stock analysis: fundamental analysis and technical analysis.
The Revelation Biosciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Revelation Biosciences' ongoing operational relationships across important fundamental and technical indicators.
Revelation |
Revelation Stock Analysis Notes
The company has price-to-book ratio of 0.57. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Revelation Biosciences recorded a loss per share of 87.68. The entity had not issued any dividends in recent years. The firm had 1:16 split on the 28th of January 2025. Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company was founded in 2020 and is based in San Diego, California. Revelation Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. To find out more about Revelation Biosciences contact James Rolke at 650 800 3717 or learn more at https://www.revbiosciences.com.Revelation Biosciences Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Revelation Biosciences' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Revelation Biosciences or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Revelation Biosciences generated a negative expected return over the last 90 days | |
| Revelation Biosciences has high historical volatility and very poor performance | |
| Revelation Biosciences has a very high chance of going through financial distress in the upcoming years | |
| Revelation Biosciences currently holds 1.91 B in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Revelation Biosciences has a current ratio of 0.67, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Revelation Biosciences' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (15.04 B) with profit before overhead, payroll, taxes, and interest of 90.91 M. | |
| Revelation Biosciences currently holds about 3.48 M in cash with (18.32 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.15. | |
| Revelation Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Revelation Biosciences, Inc. Short Interest Down 31.1 percent in February |
Revelation Biosciences Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Revelation Biosciences previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 27th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Revelation Largest EPS Surprises
Earnings surprises can significantly impact Revelation Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-09 | 2023-09-30 | -0.3 | -0.42 | -0.12 | 40 | ||
2023-08-11 | 2023-06-30 | -0.4 | -0.25 | 0.15 | 37 | ||
2022-08-15 | 2022-06-30 | -4.9 | -4.2 | 0.7 | 14 |
Revelation Biosciences Environmental, Social, and Governance (ESG) Scores
Revelation Biosciences' ESG score is a quantitative measure that evaluates Revelation Biosciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Revelation Biosciences' operations that may have significant financial implications and affect Revelation Biosciences' stock price as well as guide investors towards more socially responsible investments.
Revelation Stock Institutional Investors
| Shares | Xtx Topco Ltd | 2024-12-31 | 49.8 K | Ubs Group Ag | 2024-12-31 | 0.0 | Two Sigma Securities, Llc | 2024-12-31 | 29.1 K | Tower Research Capital Llc | 2024-12-31 | 2.5 K | Sbi Securities Co Ltd | 2024-12-31 | 301 | Royal Bank Of Canada | 2024-12-31 | 100.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 6.0 | Susquehanna International Group, Llp | 2024-12-31 | 0.0 | Pom Investment Strategies, Llc | 2024-12-31 | 0.0 | Sabby Management Llc | 2024-12-31 | 0.0 | Bank Of America Corp | 2024-12-31 | 0.0 |
Revelation Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.7 M.Revelation Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.27) | (2.38) | |
| Return On Capital Employed | (1.20) | (1.14) | |
| Return On Assets | (2.27) | (2.38) | |
| Return On Equity | (3.19) | (3.03) |
Management Efficiency
Revelation Biosciences has return on total asset (ROA) of (0.5293) % which means that it has lost $0.5293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6485) %, meaning that it created substantial loss on money invested by shareholders. Revelation Biosciences' management efficiency ratios could be used to measure how well Revelation Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 26, 2025, Return On Tangible Assets is expected to decline to -2.38. The current year's Return On Capital Employed is expected to grow to -1.14. At present, Revelation Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 3.2 M, whereas Net Tangible Assets are projected to grow to (6.7 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.7 K | 2.9 K | |
| Tangible Book Value Per Share | 2.7 K | 2.9 K | |
| Enterprise Value | 60 M | 57 M |
The leadership approach at Revelation Biosciences' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Technical Drivers
As of the 26th of March, Revelation Biosciences holds the Coefficient Of Variation of (1,542), risk adjusted performance of (0.05), and Variance of 79.0. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Revelation Biosciences, as well as the relationship between them.Revelation Biosciences Price Movement Analysis
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Revelation Biosciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Revelation Biosciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Revelation Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Revelation Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Revelation Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Revelation Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Revelation Biosciences Outstanding Bonds
Revelation Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Revelation Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Revelation bonds can be classified according to their maturity, which is the date when Revelation Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US761330AB54 Corp BondUS761330AB54 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| RETAIL PPTYS AMER Corp BondUS76131VAA17 | View | |
| US76131VAB99 Corp BondUS76131VAB99 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Revelation Biosciences Predictive Daily Indicators
Revelation Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Revelation Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Revelation Biosciences Corporate Filings
8K | 17th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 6th of March 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 30th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
8K | 21st of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of January 2025 Other Reports | ViewVerify |
Revelation Biosciences Forecast Models
Revelation Biosciences' time-series forecasting models are one of many Revelation Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Revelation Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Revelation Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Revelation Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Revelation shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Revelation Biosciences. By using and applying Revelation Stock analysis, traders can create a robust methodology for identifying Revelation entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Revelation Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Revelation analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Revelation analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 12.75 | Buy | 1 | Odds |
Most Revelation analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Revelation stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Revelation Biosciences, talking to its executives and customers, or listening to Revelation conference calls.
Revelation Stock Analysis Indicators
Revelation Biosciences stock analysis indicators help investors evaluate how Revelation Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Revelation Biosciences shares will generate the highest return on investment. By understating and applying Revelation Biosciences stock analysis, traders can identify Revelation Biosciences position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 12 B | |
| Common Stock Shares Outstanding | 1.7 M | |
| Total Stockholder Equity | 4.7 B | |
| Property Plant And Equipment Net | 56.3 K | |
| Cash And Short Term Investments | 6.5 B | |
| Cash | 6.5 M | |
| Accounts Payable | 783.6 K | |
| Net Debt | -6.5 M | |
| 50 Day M A | 4.3045 | |
| Total Current Liabilities | 1.9 M | |
| Non Current Assets Total | 56.3 M | |
| Forward Price Earnings | 0.8875 | |
| Non Currrent Assets Other | 56.3 M | |
| Stock Based Compensation | 168.8 M |
Complementary Tools for Revelation Stock analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |